A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
Price : $35 *
At a glance
- Drugs Nabilone (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 03 Feb 2017 Primary endpoint (Incidence of postoperative nausea and/or vomiting) has not been met.
- 03 Feb 2017 Results published in the Canadian Journal of Anesthesia
- 02 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.